Equities Analysts Offer Predictions for OBIO FY2025 Earnings

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) – Investment analysts at Chardan Capital decreased their FY2025 earnings per share (EPS) estimates for Orchestra BioMed in a report released on Wednesday, August 13th. Chardan Capital analyst K. Nakae now anticipates that the company will post earnings per share of ($1.77) for the year, down from their prior forecast of ($1.69). Chardan Capital currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Orchestra BioMed’s current full-year earnings is ($1.66) per share. Chardan Capital also issued estimates for Orchestra BioMed’s FY2026 earnings at ($1.44) EPS.

Orchestra BioMed (NASDAQ:OBIO) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.01. Orchestra BioMed had a negative return on equity of 289.42% and a negative net margin of 2,367.49%. The firm had revenue of $0.84 million during the quarter, compared to analyst estimates of $0.78 million.

Several other equities research analysts have also issued reports on OBIO. HC Wainwright reissued a “buy” rating on shares of Orchestra BioMed in a research note on Wednesday, April 23rd. Barclays dropped their price objective on Orchestra BioMed from $16.00 to $12.00 and set an “overweight” rating for the company in a research note on Monday, May 5th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Orchestra BioMed presently has a consensus rating of “Buy” and an average price target of $14.00.

Orchestra BioMed Price Performance

Orchestra BioMed stock opened at $2.57 on Monday. Orchestra BioMed has a one year low of $2.37 and a one year high of $7.04. The business has a fifty day moving average price of $2.98 and a 200-day moving average price of $3.46. The company has a debt-to-equity ratio of 48.76, a current ratio of 2.10 and a quick ratio of 2.09. The firm has a market capitalization of $99.30 million, a P/E ratio of -1.40 and a beta of 0.62.

Institutional Investors Weigh In On Orchestra BioMed

Several hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its stake in Orchestra BioMed by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 572,441 shares of the company’s stock worth $2,290,000 after purchasing an additional 5,222 shares during the last quarter. Boxer Capital Management LLC bought a new stake in Orchestra BioMed during the fourth quarter worth about $953,000. Northern Trust Corp lifted its stake in Orchestra BioMed by 2.5% during the fourth quarter. Northern Trust Corp now owns 236,761 shares of the company’s stock worth $947,000 after purchasing an additional 5,725 shares during the last quarter. IFP Advisors Inc lifted its stake in Orchestra BioMed by 106.4% during the first quarter. IFP Advisors Inc now owns 161,921 shares of the company’s stock worth $693,000 after purchasing an additional 83,481 shares during the last quarter. Finally, Knott David M Jr bought a new stake in Orchestra BioMed during the second quarter worth about $268,000. Institutional investors own 53.20% of the company’s stock.

Insider Transactions at Orchestra BioMed

In other news, insider David P. Hochman purchased 20,000 shares of the company’s stock in a transaction on Monday, August 4th. The stock was purchased at an average price of $2.75 per share, with a total value of $55,000.00. Following the completion of the purchase, the insider directly owned 349,331 shares in the company, valued at approximately $960,660.25. This trade represents a 6.07% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 8.10% of the company’s stock.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company’s flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.